Combinatorial approaches like CD62L+ selection with the use of cytokines promoting TSCM generation (e.g., IL-15 and IL-21) during the ex vivo expansion could further improve the enrichment of TSCM and TCM CAR T cells, and this strategy is already being developed in a clinical trial of CART19 for patients with DLBCL and others B-cell NHL lymphoma (NCT04653649). The gene discussed is SELL; the disease is diffuse large B-cell lymphoma.